BR112017006621A2 - processos para preparação de complexo de ferro (iii) com caseína n-acetil-l-aspartilada e de uma composição farmacêutica. - Google Patents
processos para preparação de complexo de ferro (iii) com caseína n-acetil-l-aspartilada e de uma composição farmacêutica.Info
- Publication number
- BR112017006621A2 BR112017006621A2 BR112017006621A BR112017006621A BR112017006621A2 BR 112017006621 A2 BR112017006621 A2 BR 112017006621A2 BR 112017006621 A BR112017006621 A BR 112017006621A BR 112017006621 A BR112017006621 A BR 112017006621A BR 112017006621 A2 BR112017006621 A2 BR 112017006621A2
- Authority
- BR
- Brazil
- Prior art keywords
- acetyl
- iii
- casein
- aspartylated casein
- aspartylated
- Prior art date
Links
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title abstract 6
- 239000005018 casein Substances 0.000 title abstract 5
- 235000021240 caseins Nutrition 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 206010022971 Iron Deficiencies Diseases 0.000 abstract 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção se refere, geralmente, a um novo processo para a preparação de complexos de caseína n-acetil-aspartilado de ferro (iii). o produto obtido de acordo com o método da presente invenção pode ser usado com segurança para a população em geral ou para animais na terapia de deficiência de ferro. o processo da invenção inclui as etapas de: (a) reação de caseína com cloreto de n-acetil-l-aspartila para formar caseína n-acetil-l-aspartilada, (b) reação subsequente da caseína n-acetil-l-aspartilada com cloreto férrico; e (c) obtenção do complexo de ferro (iii) com caseína n-acetil-l-aspartilada.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14386034.4A EP3034512B1 (en) | 2014-12-19 | 2014-12-19 | A process for producing iron (III) casein N-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions |
| EP14386034.4 | 2014-12-19 | ||
| PCT/EP2015/074482 WO2016096203A1 (en) | 2014-12-19 | 2015-10-22 | A process for producing iron (iii) casein n-acetyl-aspartylated complexes and use thereof in pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017006621A2 true BR112017006621A2 (pt) | 2017-12-19 |
| BR112017006621B1 BR112017006621B1 (pt) | 2023-11-07 |
Family
ID=52354737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017006621-1A BR112017006621B1 (pt) | 2014-12-19 | 2015-10-22 | Processos para preparação de complexo de ferro (iii) com caseína nacetil-l-aspartilada e de uma composição farmacêutica |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20170340747A1 (pt) |
| EP (1) | EP3034512B1 (pt) |
| AP (1) | AP2017009801A0 (pt) |
| AU (1) | AU2015365885B2 (pt) |
| BR (1) | BR112017006621B1 (pt) |
| CA (1) | CA2959226C (pt) |
| CL (1) | CL2017001611A1 (pt) |
| CO (1) | CO2017003313A2 (pt) |
| CY (1) | CY1120037T1 (pt) |
| DK (1) | DK3034512T3 (pt) |
| EA (1) | EA031968B1 (pt) |
| ES (1) | ES2655238T3 (pt) |
| GE (1) | GEP20207081B (pt) |
| HR (1) | HRP20171965T1 (pt) |
| HU (1) | HUE035302T2 (pt) |
| IL (1) | IL251449B (pt) |
| LT (1) | LT3034512T (pt) |
| MX (1) | MX2017008100A (pt) |
| MY (1) | MY185391A (pt) |
| NO (1) | NO3034512T3 (pt) |
| PE (1) | PE20180660A1 (pt) |
| PH (1) | PH12017500391B1 (pt) |
| PL (1) | PL3034512T3 (pt) |
| PT (1) | PT3034512T (pt) |
| RS (1) | RS56714B1 (pt) |
| SA (1) | SA517381261B1 (pt) |
| SG (1) | SG11201702593TA (pt) |
| SI (1) | SI3034512T1 (pt) |
| WO (1) | WO2016096203A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1009589B (el) * | 2018-04-05 | 2019-09-11 | Ιουλια Κλεωνος Τσετη | Φαρμακευτικο σκευασμα για την αντιμετωπιση της αναιμιας, σε καταλληλο περιεκτη, που διατηρει στεγανα διαχωρισμενα μεταξυ τους τα δραστικα συστατικα: συμπλοκο του τρισθενους σιδηρου με ν-ακετυλο-l-ασπαρτικη καζεϊνη και πενταϋδρικο φυλλινικο ασβεστιο |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB910321A (en) | 1960-02-25 | 1962-11-14 | Olivier Paul Gaudin | Improvements in and relating to a process for preparing ferrous salts of aspartic acid and medicines containing these salts |
| IT1150213B (it) | 1982-03-02 | 1986-12-10 | Italfarmaco Spa | Derivati di ferro biodisponibile esenti da gastrolesivita',procentimento di preparazione e relative composizioni farmaceutiche |
| IT1207996B (it) | 1986-03-18 | 1989-06-01 | Magis Farmaceutici | Composti contenenti ferro biodisponibile, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. |
| GB9621273D0 (en) | 1996-10-11 | 1996-11-27 | Cortecs Ltd | Therapeutic method |
| IT1297022B1 (it) | 1997-12-24 | 1999-08-03 | Chemi Spa | Complesso di ferro-succinilcaseina, processo per la sua preparazione e composizioni farmaceutiche che lo contengono |
| ITMO20040200A1 (it) | 2004-07-29 | 2004-10-29 | Biofer Spa | Processo per la produzione di complessi ferro succinilcaseina e ferro casein acetil aspartilato e loro utilizzato nelle relative composizioni farmaceutiche. |
-
2014
- 2014-12-19 EP EP14386034.4A patent/EP3034512B1/en active Active
- 2014-12-19 RS RS20171312A patent/RS56714B1/sr unknown
- 2014-12-19 SI SI201430535T patent/SI3034512T1/en unknown
- 2014-12-19 LT LTEP14386034.4T patent/LT3034512T/lt unknown
- 2014-12-19 PL PL14386034T patent/PL3034512T3/pl unknown
- 2014-12-19 PT PT143860344T patent/PT3034512T/pt unknown
- 2014-12-19 DK DK14386034.4T patent/DK3034512T3/en active
- 2014-12-19 NO NO14386034A patent/NO3034512T3/no unknown
- 2014-12-19 ES ES14386034.4T patent/ES2655238T3/es active Active
- 2014-12-19 HU HUE14386034A patent/HUE035302T2/en unknown
-
2015
- 2015-10-22 MX MX2017008100A patent/MX2017008100A/es active IP Right Grant
- 2015-10-22 MY MYPI2017701462A patent/MY185391A/en unknown
- 2015-10-22 CA CA2959226A patent/CA2959226C/en active Active
- 2015-10-22 AU AU2015365885A patent/AU2015365885B2/en active Active
- 2015-10-22 PE PE2017000363A patent/PE20180660A1/es unknown
- 2015-10-22 AP AP2017009801A patent/AP2017009801A0/en unknown
- 2015-10-22 WO PCT/EP2015/074482 patent/WO2016096203A1/en active Application Filing
- 2015-10-22 BR BR112017006621-1A patent/BR112017006621B1/pt active IP Right Grant
- 2015-10-22 EA EA201790902A patent/EA031968B1/ru unknown
- 2015-10-22 US US15/536,855 patent/US20170340747A1/en not_active Abandoned
- 2015-10-22 SG SG11201702593TA patent/SG11201702593TA/en unknown
- 2015-10-22 GE GEAP201514514A patent/GEP20207081B/en unknown
-
2017
- 2017-03-02 PH PH12017500391A patent/PH12017500391B1/en unknown
- 2017-03-29 IL IL251449A patent/IL251449B/en active IP Right Grant
- 2017-04-05 SA SA517381261A patent/SA517381261B1/ar unknown
- 2017-04-05 CO CONC2017/0003313A patent/CO2017003313A2/es unknown
- 2017-06-19 CL CL2017001611A patent/CL2017001611A1/es unknown
- 2017-12-19 HR HRP20171965TT patent/HRP20171965T1/hr unknown
- 2017-12-21 CY CY20171101341T patent/CY1120037T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023001189A (es) | Produccion de acido ribonucleico libre de celulas. | |
| MX2018013099A (es) | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5- il)-piridin-3-il)metoxi)benzaldehido. | |
| MX360863B (es) | Ácidos 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso. | |
| MY191236A (en) | Diorganylphosphinic acid salts, method for the production thereof and the use thereof | |
| BR112015031913A2 (pt) | processo para a fabricação de amino-benzoxazinonas 4-propargilatadas e sua utilização | |
| PH12018501362A1 (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| BR112018013833A2 (pt) | métodos de administração de hepcidina | |
| MX2023005704A (es) | Metodo para manufacturar compuesto novedoso que contiene nitrogeno o sal del mismo e intermediario de manufacturacion del compuesto novedoso que contiene nitrogeno o sal del mismo. | |
| MY193444A (en) | Cell-free production of ribonucleic acid | |
| BR112017027048A2 (pt) | processo para extração de pectina e uso da pectina | |
| AR090566A1 (es) | Proceso para la produccion de inhibidores de crr | |
| BR112019000521A2 (pt) | forma de cristal de intermediário de dapagliflozina e método de preparação do mesmo | |
| BR112017020053A2 (pt) | novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo | |
| MY196473A (en) | 7-Substituted 1-Aryl-Naphthyridine-3-Carboxylic Acid Amides and use Thereof | |
| BR112017006621A2 (pt) | processos para preparação de complexo de ferro (iii) com caseína n-acetil-l-aspartilada e de uma composição farmacêutica. | |
| EA201790321A1 (ru) | Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими | |
| EA201390867A1 (ru) | Композиции на основе глины и обножки, способ их получения и их применение в питании и терапевтическом лечении | |
| BR112018007505A2 (pt) | processo industrial para a preparação de sal de (e)-3-carboxiacrilato de (5s,10s)-10-benzil-16-metil-11,14,18-trioxo-15,17,19-trioxa-2,7,8-tritia-12-aza-henicosan-5-amínio | |
| BR112017005614A2 (pt) | processo para preparação de complexos de hidróxido de ferro (iii) e xarope de glicose ativado, complexo de hidróxido de ferro (iii) e xarope de glicose, e, composição farmacêutica. | |
| BR112018000682A2 (pt) | processo para a preparação de um produto de leite fermentado | |
| BR112017009308A2 (pt) | método de produção de excipiente de copolímero de enxerto com uma propriedade de ligação a proteína e peptídeo superior | |
| JO3484B1 (ar) | عملية إنتاج مركبات كازين الحديد ( n ( iii -أسيتيل الأسبرتيل واستخدامها في التركيبات الصيدلانية | |
| MX2016005220A (es) | Tinturas acidas, proceso para su produccion y su uso. | |
| ZA202201221B (en) | Cyclopentane compounds | |
| UA90818U (uk) | Спосіб отримання сполуки з потенційними фізіологічними властивостями 1-1-діетилкарбоксі-2-ізопропокси-2-трифторметилетилен |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 22/10/2015, OBSERVADAS AS CONDICOES LEGAIS |